Difference between revisions of "Talk:Main Page"

Revision as of 05:39, 16 August 2014 (view source) 62.210.142.7 (talk) (magic story very thanks <a href=" http://www.gym64.com/testimonials ">paxil online petition</a> Turnover from Glivec/Gleevec (imatinib), for chronic myeloid leukaemia and gastrointestinal stromal tum) ← Older edit		Latest revision as of 13:45, 17 October 2014 (view source) Jmonaco (talk \| contribs) (Blanked the page)
Line 1:		Line 1:
−	magic story very thanks <a href=" http://www.gym64.com/testimonials ">paxil online petition</a> Turnover from Glivec/Gleevec (imatinib), for chronic myeloid leukaemia and gastrointestinal stromal tumours was down 3% at $1.13 billion, while the successor to Glivec, Tasigna (nilotinib), also approved for CML, contributed $315 million, up 21%.	+

Latest revision as of 13:45, 17 October 2014